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INTRODUCTION
Endoscopic injection for the treatment of vesicoureteral 
reflux (VUR) was initially introduced by Matouschek in 
1981, and O’Donnell and Puri [1] reported the first clinical 
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results in 1984. After the United States (US) Food and 
Drug Administration (FDA) approved dextranomer/
hyaluronic acid copolymer (Dx/HA, Deflux; Q-Med, Scandi-
navia, Uppsala, Sweden) for the treatment of VUR in 2001, 
endoscopic injection has gained popularity because of its 
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substantial benefits, including straightforward technique, 
minimal invasiveness, low rate of  complications, and 
acceptable success rate. This has been accompanied by a 
reevaluation of  the treatment philosophy for VUR, and 
some urologists even recommend endoscopic injection as 
first-line treatment for VUR [2,3].
The ideal substance for injection therapy should have 
two major characteristics. The first is “anatomic integrity”, 
enabling the material to pass through the endoscope and 
maintain its volume over time. The other component is 
“material safety”, which requires biocompatibility and 
lack of  migration from the site of  injection. Since the 
first use of polytetrafluoroethylene (Teflon) as a bulking 
agent for treating reflux, various materials such as poly-
dimethylsiloxane (PDMS, Macroplastique; Uroplasty, Inc., 
Minnetonka, MN, USA) and autologous materials have been 
proposed as alternative agents. However, several drawbacks, 
including particle migration and low efficacy, have limited 
usage of  these agents. For the last decade, Dx/HA has 
become the most popular bulking agent worldwide because 
of its safety and efficacy [4]. Nevertheless, there is a paucity 
of evidence-based literature regarding the long-term effects 
of Dx/HA injection for VUR. The biodegradable nature of 
Dx/HA has been identified as a possible cause for the high 
recurrence rate during follow-up, emphasizing the need to 
continue the search for alternative substances for injection 
therapy [5].
A recently developed dermal filler consisting of poly-
methylmethacrylate (PMMA) and cross-linked dextran 
(PMMA/Dx, Dexol; Chungwha Medipower Corporation, 
Seoul, Korea) demonstrated good efficacy and durability for 
soft tissue augmentation, without complications [6]. PMMA, 
a synthetic non-biodegradable material, has been used in 
cosmetic surgery with a good safety record [7]. It consists 
of 32 to 120 mm microspheres with a smooth surface and 
maintains its volume more than 10 years after injection 
[8]. Cross-linked dextran (dextranomer) has been used for 
wound-healing purposes and is a key ingredient in Dx/HA. 
We conducted a prospective study to evaluate the efficacy of 
PMMA/Dx in children with primary VUR during 3-month 
follow-up.
MATERIALS AND METHODS
1. Patients
This is a single-center, prospective, of f-label study 
performed by a single surgeon (SW Han). The protocol was 
approved by the committee of ethics of research protocols at 
Severance Hospital (approval number: 1-2012-0057). Parents 
signed an informed consent form for each patient. We 
selected children under the age of 7 years with Grade I to 
V VUR requiring correction, whose parents understood 
and agreed with the purpose of study. Every child had a 
recent preoperative voiding cystourethrogram (VCUG) and 
dimercaptosuccinic acid (DMSA) renal scan. Preoperative 
urine cultures were collected from all patients, and sterile 
urine was confirmed before patients underwent endoscopic 
injection. The indications for endoscopic correction in the 
majority of patients were breakthrough infections during 
antibiotic prophylaxis or persistent high-grade VUR. In some 
patients, reflux correction was performed at the request of 
parents.
The exclusion criteria consisted of neurogenic bladder, 
reflux secondary to another anatomical malformation of 
the urinary tract (e.g., obstruction, duplex system), pre-
vious surgical or endoscopic procedures, and suspected or 
confirmed dysfunctional voiding by clinical findings or 
abnormal results (e.g., irregular bladder wall, diverticulum) 
on VCUG. Children with paraureteral diverticulum on 
VCUG were also excluded. According to our standard 
protocol, all patients underwent VCUG and renal ultrasound 
at 3 months postoperatively to evaluate correction of reflux 
and absence of de novo or worsening hydronephrosis. Reflux 
Grade I or less at this follow-up evaluation was defined as 
success. DMSA renal scan at 1 year after their first injection 
was planned. Patients continued antibiotic prophylaxis until 
VUR resolution was demonstrated on VCUG.
2. Injection material
The PMMA/Dx agent consists of  75% cross-linked 
dextran and 15% PMMA; it was approved by the Korean 
FDA for soft tissue augmentation in 2010. Cross-linked 
dextran and PMMA are microspheres with diameters of 45 
to 120 mm and 32 to 120 mm, respectively. These microspheres 
account for 90% of  the volume and are suspended in 
hypromellose solution, which comprises the other 10%. This 
bulking agent is biocompatible, nonresorbable microparticle-
free and migration resistant.
3. Technique
While the patient received general anesthesia, endoscopic 
treatment was performed with a 21-gauge needle and 
1ml syringe of PMMA/Dx using a 10-Fr cystoscope (Karl 
Storz, Tuttlingen, Germany). All injection was performed 
using subureteric transurethral injection (STING) or 
hydrodistention implantation technique (HIT), or a 
combination of both techniques, depending on the anatomy 
of the ureteral meatus and the surgeon’s preference. The 
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surgeon had an extensive experience of  more than a 
thousand cases with previous injection materials, including 
Dx/HA and PDMS. 
4. Statistics
The primary outcome was surgical success on post-
operative VCUG. Secondary outcomes included the occu-
rrence of adverse events. We planned to recruit a sufficient 
number of patients to have 30 ureters treated with PMMA/
Dx injections, expecting a 5% to 10% loss to follow-up. All 
data analyses were performed using IBM SPSS Statistics 
ver. 20.0 (IBM Co., Armonk, NY, USA). 
RESULTS
Patient demographics are presented in Table 1. A total of 
18 patients underwent endoscopic treatment of VUR using 
PMMA/Dx at Severance Hospital between April 2013 and 
December 2013. VUR was unilateral in three and bilateral 
in 15, comprising 33 renal refluxing units (RRUs). VUR 
was Grade I in one RRU, Grade II in 12 RRUs, Grade III 
in 16 RRUs, and Grade IV in four RRUs. Recurrent febrile 
urinary tract infections (UTIs) served as the only indication 
for surgery in 13 patients (72.2%), Grade IV VUR was the 
indication in three patients (16.7%), and parental request for 
reflux correction was the indication in two patients (11.1%). 
The STING technique was used in 20 RRUS, whereas HIT 
or combination of both techniques was adopted in the other 
13 RRUs to create the appearance of a “volcanic bulge” (Fig. 
1).
The VCUG results at 3 months postoperatively are 
summarized in Table 2. Overall, the endoscopic injection 
corrected VUR in 23 of 33 RRU (69.7%) at 3 months. Of the 
four patients (4 ureters) who demonstrated improvement 
of reflux to Grade I, none received further treatment, and 
no complications such as febrile UTI occurred. In nine 
patients (10 ureters) with residual VUR greater than 
Grade I (failures), postoperative VUR was downgraded to 
Grade II in six ureters and Grade III in one ureter, and 
three ureters demonstrated no change after injection. In 
these nine patients with residual VUR, one patient with 
remnant bilateral VUR of Grades II and III had a suspected 
febrile UTI and underwent ureteral reimplantation. The 
other eight patients developed no UTI and underwent no 
Table 1. Patient demographics at baseline
Variable Value
Number of patients 18
Gender
   Male 10
   Female 8
Number of RRUs 33
Laterality
   Unilateral 3
   Bilateral 15
RRU grade (n=33)
   I 1 (3.0)
   II 12 (36.4)
   III 16 (48.5)
   IV 4 (12.1)
Indications for surgery
   Breakthrough UTI 13 (72.2)
   Persistent high-grade VUR 3 (16.7)
   Parents’ request 2 (11.1)
Incidence of cortical defect on renal scan (n=33) 15 (45.5)
Age at surgery (mo) 48 (31–62)
Injected volume (mL) 0.91±0.384
Values are presented as number only, number (%), median (interquar-
tile range), or mean±standard deviation. 
RRU, renal refluxing unit; UTI, urinary tract infection;  VUR, vesicoure-
teral reflux.
Fig. 1. (A) preoperative cystoscopic find-
ing, (B) competent ureteral orifice on 
the top of a “volcano” after injection of 
polymethylmethacrylate/dextranomer 
injection.
A B
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further treatment during follow-up. Except one patient 
who underwent postoperative DMSA scan after ureteral 
reimplantation, follow-up renal scan was performed 1 year 
after endoscopic injection and no newly developed cortical 
defect was seen after either of  successful or even failed 
injection.
Postoperative complications included urinary retention 
developed in one patient, which improved after 2 weeks of 
urethral catheterization. In one patient, mild pyelectasis was 
noted on ultrasonography at 3 months, which spontaneously 
resolved 3 months later. No significant complications such 
dysuria, allergic reaction, lumbar pain were identified.
DISCUSSION
To our knowledge, this is the first study to evaluate the 
efficacy of PMMA/Dx for treating patients with VUR via 
endoscopic injection. The results of this preliminary study 
were satisfactory, with a success rate of 69.7% RRUs. Given 
that the reported success rates with Dx/HA range from 68% 
to 92% [9], the success rates in this study are comparable 
to those obtained with other substances currently in use. 
No significant complications were identified. Furthermore, 
with the documented nonabsorbable property of PMMA/Dx, 
we do not anticipate that there will be a significant loss of 
implant volume over time.
Endoscopic injection therapy changed the treatment 
paradigm of VUR after Dx/HA was approved by the US 
FDA in 2001, and the number of children with VUR treated 
with injection therapy dramatically increased between 2002 
and 2006 [2]. However, debate continues regarding the ideal 
bulking agent for endoscopic therapy of VUR. Currently, 
the most popular bulking agent is Dx/HA. This is a highly 
hydrophilic dextran polymer with a good safety profile and 
a base of nonanimal-stabilized HA, which is easily injected 
by manual pressure without the need for an injection gun. 
Endoscopic injection with Dx/HA demonstrated an overall 
mean success rate of  77% and infrequent complications 
following the procedure [4]. However, with increasing usage 
of  Dx/HA, concerns have emerged regarding long-term 
durability and complications of injection therapy.
There have been several reports of successful long-term 
results with Dx/HA [10,11]. Nevertheless, routine follow-up 
VCUG was not conducted in most studies, which reduced 
the validity of their results, and declining success rates over 
time have been reported [5,12]. One possible explanation for 
the decreasing success rate is movement of the injection 
material. Lee et al. [12] reported that Dx/HA was no 
longer located at the initial injection site when ureteral 
reimplantation was performed after failed injection therapy. 
Its biodegradable nature also likely contributes to the 
decreasing efficacy of Dx/HA over time. Although Dx acts as 
a cell attractant material, specifically recruiting fibroblasts 
that synthesize new collagen and thereby resulting in 
endogenous tissue augmentation, it is slowly degraded 
within the body by hydrolysis. Furthermore, most of the HA 
disappears within several weeks after injection [13]. Stenberg 
et al. [14] observed that implant volume was reduced by 
23% at 1 year after subcutaneous implantation of  Dx/
HA in rats. Similarly, in children, the injected volume was 
reduced by 20% at 2 weeks after injection and continued to 
slowly decrease during follow-up (albeit not at a statistically 
significant rate) [15].
Many bulking agents have been investigated throughout 
the years to overcome the limitations of Dx/HA. The most 
notable material developed recently is a polyacrylate 
polyalcohol bulking copolymer (PPC, Vantris; Promedon, 
Cordoba, Argentina), which is a new non-biodegradable 
substance of  synthetic origin belonging to the acrylic 
family. It was first introduced in 2010 for the treatment 
of VUR [16], and its large average diameter of 320 nm and 
non-biodegradable nature may produce better stability 
and long-term durability in treating VUR. Several studies 
reported successful short-term outcomes (88.6% to 93.8% 
VUR resolution rate) with PPC, which are similar or even 
superior to those reported with Dx/HA [17,18]. However, 
ureteral obstruction was more commonly seen with PPC 
than with Dx/HA [19], and a recent animal study revealed 
Table 2. Outcome of single endoscopic injection of polymethylmethacrylate/dextranomer in 33 RRUs with regard to the initial VUR grade at 
3-month follow-up
VUR grade No. of RRUs No. of improved to Grade I No. of failures Success rate (%)
I 1 0 0 100.0
II 12 2 1 91.7
III 16 1 7 56.3
IV 4 1 2 50.0
Total 33 4 10 69.7
RRU, renal refluxing unit; VUR, vesicoureteral reflux.
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that PPC led to severe fibrosis at the injection site [20]. These 
results have raised concerns regarding the possibility of 
ureteral obstruction after PPC injection and thereby limited 
the use of this material.
PMMA/Dx (Dexol), a PMMA and cross-linked dextran 
mixture, is a newly developed dermal filler for soft tissue 
augmentation, which is a commercially-available product 
approved by the Korean FDA in 2010. PMMA microspheres, 
fine spherical particles with a size of  45 μm to 120 μm 
(mean, 100 μm), are not subjected to phagocytosis because 
of  their large molecular size. Furthermore, some PMMA 
microspheres are encapsulated by connective tissue 
consisting of  fibroblasts, which inhibits their migration 
to other tissues and subsequent volume loss. In addition, 
PMMA is not degraded by enzymes in vivo. Dextran also 
stimulates fibroblasts after being absorbed by macrophages 
and is therefore replaced by autologous tissue, resulting in 
minimal loss of volume [21,22]. In an animal study comparing 
PMMA/Dx and Dx/HA, PMMA/Dx maintained its shape 
better at the injection site, even after 3 weeks, and showed 
significantly better volume maintenance [22]. Initial clinical 
reports with PMMA/Dx for soft tissue augmentation 
demonstrated that the material led to a significant increase 
in soft tissue volume and was well-circumscribed within 
the human subcutaneous tissue, without producing serious 
adverse events, such as inflammation or necrosis [23]. A 
subsequent long-term study also showed good durability and 
tolerability without volume loss over 18 months of follow-up 
[6].
Complications with Dx/HA injection mainly relate to 
obstruction at the injection site. Since the first report by 
Snodgrass [24] in 2004, publications on postoperative obs-
truction have been scarce and the reported incidence has 
been very low [24-26]. However, obstruction may simply 
be not identified, resulting in silent loss of renal function. 
Ureteral obstruction after injection therapy is usually due 
to extensive inflammation, with foreign body reaction and 
granuloma formation [26]. PMMA has been safely used as 
a dermal filler for more than 20 years with an incidence 
of granuloma formation below 0.2% [27]. A previous animal 
study revealed that infiltration of inflammatory cells or 
macrophages did not occur at the injection site with PMMA/
Dx [22]. Foreign body reactions, such as granulomas, were not 
observed in any animal, which was similar to the findings 
with Dx/HA. In our current study, postoperative ultrasound 
demonstrated well-positioned material at the injection site, 
with no evidence of  obstruction during our short-term 
follow-up period (3 months). Given that delayed obstruction 
could occur as late as 5 years after injection therapy, long-
term follow-up is required to confirm these results. Another 
concern for injection material is a particle migration, which 
limited the use of polytetrafluoroethylene. However, in a 
previous animal study, it was demonstrated that the average 
particle size of PMMA more than 40 μm prevents migration 
to other organs [28]. Considering that the average particle 
size of PMMA in the mixture was 100 μm, PMMA/Dx can 
be safely used into ureter without migration.
Some study limitations should be mentioned. First, the 
duration of follow-up was not sufficient to confirm the long-
term effects or complications of  the PMMA/Dx mixture. 
Another limitation is the absence of  a control group in 
our series and a slightly lower success rate compared with 
previous results of  Dx/HA. In our experience, due to a 
different particle size of PMMA/Dx from previous materials, 
a learning curve with the material to be accustomed to a 
tactile sensation and development of the mound is required. 
In addition, the small number of subjects included in our 
study impeded to conclude a precise comparative outcome, 
Nevertheless, the observed success rate suggests that 
further trials comparing PMMA/Dx and Dx/HA would be 
worthwhile. The results of the current study demonstrated 
that injection of PMMA/Dx beneath the mucosal layer of a 
refluxing ureter is safe, well tolerated, easy to perform, and 
effective. Additionally, the non-biodegradable nature of this 
material might be expected to have a long-term durability.
CONCLUSIONS
Off-label use of  PMMA/Dx for injection therapy in 
primary VUR reveals that short-term success rates are 
69.7%, which are comparable to those reported for the 
currently used bulking agent. PMMA/Dx may be a new 
effective material for endoscopic injection therapy in 
children with VUR. Long-term follow-up to confirm the 
durability and prolonged efficacy are necessary to confirm 
the usefulness of this material in treating VUR.
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